Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Arteaus Therapeutics, LLC

http://www.arteaus.com/

Latest From Arteaus Therapeutics, LLC

Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties

Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.

Financing StartUps and SMEs

Appointments: New CEOs For Lundbeck, Voyager & Neos, CSOs For iTeos & Tilos

Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.

Appointments Leadership

Pipeline Watch: Phase III Starts For Seres' SER-109, Leo's Tralokinumab And Alkermes' ALKS-5461

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.

Market Intelligence Research and Development Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register